Source:http://linkedlifedata.com/resource/pubmed/id/20347317
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0037949,
umls-concept:C0038477,
umls-concept:C0220781,
umls-concept:C0237881,
umls-concept:C0243077,
umls-concept:C0285558,
umls-concept:C0750502,
umls-concept:C0812228,
umls-concept:C1704675,
umls-concept:C1705328,
umls-concept:C1705341,
umls-concept:C1883254,
umls-concept:C2603343,
umls-concept:C2936235
|
pubmed:issue |
8
|
pubmed:dateCreated |
2010-4-12
|
pubmed:abstractText |
Elevated levels of activated Protein Kinase B (PKB/Akt) have been detected in many types of human cancer. In contrast to ATP site inhibitors, substrate-based inhibitors are more likely to be selective because of extensive interactions with the specific substrate binding site. Unfortunately, peptide-based inhibitors lack important pharmacological properties that are required of drug candidates. Chemical modifications of potent peptide inhibitors, such as peptoids and N(alpha)-methylated amino acids, may overcome these drawbacks, while maintaining potency. We present a structure-activity relationship study of a potent, peptide-based PKB/Akt inhibitor, PTR6154. The study was designed to evaluate backbone modifications on the inhibitory activity of PTR6154. Two peptidomimetic libraries, peptoid and N(alpha)-methylation, based on PTR6154, were synthesized and evaluated for in vitro PKB/Akt inhibition efficiency. All the peptoid analogs reduced potency significantly, as well as most of the members of the N-methyl library, suggesting that the backbone conformation and/or hydrogen bond interactions of PTR6154 derivatives are essential for inhibition activity. Two N-terminal members of the N-methyl library did not decrease potency and can be used as future drug leads.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Oligopeptides,
http://linkedlifedata.com/resource/pubmed/chemical/Peptoids,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-akt
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
1464-3391
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 2010 Elsevier Ltd. All rights reserved.
|
pubmed:issnType |
Electronic
|
pubmed:day |
15
|
pubmed:volume |
18
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2976-85
|
pubmed:meshHeading |
pubmed-meshheading:20347317-Amino Acid Sequence,
pubmed-meshheading:20347317-Antineoplastic Agents,
pubmed-meshheading:20347317-Binding Sites,
pubmed-meshheading:20347317-Oligopeptides,
pubmed-meshheading:20347317-Peptoids,
pubmed-meshheading:20347317-Protein Kinase Inhibitors,
pubmed-meshheading:20347317-Proto-Oncogene Proteins c-akt,
pubmed-meshheading:20347317-Structure-Activity Relationship
|
pubmed:year |
2010
|
pubmed:articleTitle |
Synthesis and structure-activity relationship studies of peptidomimetic PKB/Akt inhibitors: the significance of backbone interactions.
|
pubmed:affiliation |
Institute of Chemistry, The Hebrew University of Jerusalem, 91904 Jerusalem, Israel.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|